Imbalance between alpha-1-antitrypsin and interleukin 6 is associated with in-hospital mortality and thrombosis during COVID-19

[1]  Borghi Claudio,et al.  Pulmonary Embolism in Patients with COVID-19 , 2022, Clinical Cardiology and Cardiovascular Interventions.

[2]  B. Nordestgaard,et al.  α1 -antitrypsin Z allele and risk of venous thromboembolism in the general population. , 2021, Journal of thrombosis and haemostasis : JTH.

[3]  A. Griffioen,et al.  COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects , 2021, Angiogenesis.

[4]  A. Lindberg,et al.  Severe alpha‐1‐antitrypsin deficiency increases the risk of venous thromboembolism , 2021, Journal of thrombosis and haemostasis : JTH.

[5]  Yasser B. Ruiz-Blanco,et al.  Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection , 2021, Nature Communications.

[6]  A. Duhamel,et al.  Protease-antiprotease imbalance in patients with severe COVID-19 , 2021, Clinical chemistry and laboratory medicine.

[7]  Sean C. Yu,et al.  The Clinical Course of Coronavirus Disease 2019 in a US Hospital System: A Multistate Analysis , 2020, American journal of epidemiology.

[8]  E. Messas,et al.  Predictive Factor for COVID-19 Worsening: Insights for High-Sensitivity Troponin and D-Dimer and Correlation With Right Ventricular Afterload , 2020, Frontiers in Medicine.

[9]  A. Borczuk,et al.  COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City , 2020, Modern Pathology.

[10]  Michael D Healy,et al.  SARS-CoV-2 viral load is associated with increased disease severity and mortality , 2020, Nature Communications.

[11]  R. Favory,et al.  Pulmonary Embolism in Patients With COVID-19 , 2020, Circulation.

[12]  N. McElvaney,et al.  Characterization of the Inflammatory Response to Severe COVID-19 Illness , 2020, American journal of respiratory and critical care medicine.

[13]  Mike Clarke,et al.  A minimal common outcome measure set for COVID-19 clinical research , 2020, The Lancet Infectious Diseases.

[14]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[15]  R. Stockley.  The multiple facets of alpha-1-antitrypsin. , 2015, Annals of translational medicine.

[16]  D. Lomas,et al.  α1-antitrypsin deficiency , 2005, The Lancet.

[17]  S. Larsson,et al.  Inhibition of lipopolysaccharide-mediated human monocyte activation, in vitro, by alpha1-antitrypsin. , 2004, Biochemical and biophysical research communications.

[18]  R. Bertina,et al.  A Second Plasma Inhibitor of Activated Protein C: α1-Antitrypsin , 1989, Thrombosis and Haemostasis.

[19]  Raghav Gupta,et al.  A rare case of alpha 1-antitrypsin deficiency associated with hypogammaglobulinemia and recurrent pulmonary thrombosis , 2014, Annals of thoracic medicine.

[20]  N. Porchet,et al.  Evaluation of a new Sebia isoelectrofocusing kit for α1-antitrypsin phenotyping with the Hydrasys® System , 2008, Clinical chemistry and laboratory medicine.